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doi:10.1016/j.ijid.2004.08.001Summary A number of surgical and non-surgical options exist to treat cystic
echinococcosis of the liver. For decades, surgical excision via a conservative or radical
approach was the recommended approach for hepatic hydatid cysts. The availability
of chemotherapeutic agents with significant activity against Echinococcus granulosis
has made it possible to undertake ultrasound- or computed tomography-guided
transhepatic percutaneous drainage (termed puncture, aspiration, injection, and
re-aspiration (PAIR)) of hydatid cysts. Pre- and post-intervention chemotherapy with
albendazole or mebendazole offers the advantage of reducing the risk of disease
recurrence and intraperitoneal seeding of infection that may develop via cyst rupture
and spillage occurring spontaneously or during surgery or needle drainage. PAIR
appears to have greater clinical efficacy (i.e. a higher incidence of cure), lower
rates of major and minor complications, mortality, and disease recurrence, and fewer
days of hospitalization compared to patients treated surgically. For patients who fail
drug therapy alone, PAIR is a safe and effective procedure of choice for patients with
hepatic echinococcosis, and perhaps other anatomic sites of infection such as lung,
peritoneum, kidney, and other viscera. Surgery should be reserved for patients with
hydatid cysts refractory to PAIR because of secondary bacterial infection or for those
with difficult-to-manage cyst-biliary communication or obstruction.
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Human cystic echinococcosis, or hydatid cyst dis-
ease, is a zoonosis caused by the larval cestode
Echincoccus granulosus. Hippocrates recognized
hydatid disease over 2000 years ago, and the disease
remains endemic today in sheep-raising areas of the
world including Africa, the Mediterranean region ofnal Society for Infectious Diseases.
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tralia, and New Zealand. Dogs are the definitive
hosts for E. granulosus and sheep the major inter-
mediate host (yaks, goats, and camels are other
relevant intermediate hosts); man is only inciden-
tally infected. The liver is the most frequent site for
the cystic lesions seen in hydatid disease, followed
by the lung, brain, and other viscera.1
Three therapeutic modalities exist to treat hepa-
tic cystic echinococcosis: chemotherapy, surgery,
and percutaneous drainage (with the latter two
being performed with or without chemotherapy).
Historically, management of hydatid cysts in the
liver typically involved an open surgical approach
with meticulous operative site packing, and
employed a variety of conservative and radical
operative techniques.2—4 Percutaneous aspiration
of a documented or suspected hydatid cyst was long
considered contraindicated in order to avoid the risk
of leakage of cyst contents, which can lead to
anaphylaxis and seeding of intraperitoneal struc-
tures. Since the advent of drug therapy effective
against Echinococcus species, the use of pre- and
postoperative chemotherapy with albendazole or
mebendazole combined with percutaneous drainage
(consisting of puncture, aspiration, injection, and
re-aspiration, or PAIR) of hepatic hydatid cysts is
now widely advocated.4—8
This article reviews the available surgical and
non-surgical approaches used to treat cystic echi-
nococcosis of the liver, and summarizes the safety
and effectiveness of percutaneous drainage plus
antiparasitic drug therapy compared to surgical
interventions.Antiparasitic chemotherapy
Mebendazole and albendazole
Mebendazole was the first benzimidazole carbamate
agent found to have in vivo activity in hydatid
disease. The drug interferes with mechanisms of
glucose absorption through the wall of the parasite
leading to glycogen depletion and subsequent
degenerative changes in the mitochondria and
endoplasmic reticulum of the germinal cells.9
Albendazole is more active in vitro than mebenda-
zole and has improved gastrointestinal absorption
and bioavailability, as well as reports of better
clinical results.10—15 After oral administration,
albendazole is converted by first-pass hepatic meta-
bolism to the active metabolite, albendazole sulf-
oxide, achieves variable concentrations in blood,
bile, liver tissue, cyst fluid, and cyst wall, and
crosses the blood-brain barrier.14,16,17 Althoughorally administered, albendazole results in high
serum concentrations (peaking in about four hours,
and with a serum half-life of 6—15 hours) and pene-
tration into cyst contents is erratic.
Important drug interactions exist for albendazole
and dexamethasone,18—20 praziquantel,18—20 cime-
tidine,21,22 and antiepileptic drugs (phenytoin, car-
bamazepine, and phenobarbital)23; all increase drug
bioavailability with enhanced levels of the active
metabolite, albendazole sulfoxide. In contrast, clo-
trimazole abolishes in vitro microsomal sulfonase
activity and results in inhibition of the formation of
active and inactive metabolites of albendazole.24
Both drugs may decrease the size of hydatid cysts
and may lead to the sterilization of cyst contents in
some cases;25 however, without concomitant drai-
nage clinical and radiographic resolution is unpre-
dictable and occurs in less than half of treated
patients.10—14,17,26 Percutaneous injection of
mebendazole or albendazole sulfoxide without re-
aspiration has been attempted in both experimental
and human subjects and results in effective scoli-
cidal activity with little or no toxicity to the liver or
biliary system, and local instillation has been sug-
gested as an adjunctive to systemic chemother-
apy.27,28 The usual dose of orally-administered
albendazole, with or without PAIR, is 10—15 mg/
kg/day in two divided doses, or as a fixed dose of
400 mg bid. If mebendazole is used, the daily dose is
40—50 mg/kg in three divided doses. Hepatic and
hematologic toxicities are the most frequent serious
adverse effects of albendazole and mebendazole.
For patients receiving drug therapy it is generally
recommended to have liver enzymes and complete
blood counts monitored every two weeks during
drug treatment.29
Treatment of hepatic cystic echinococcosis
with mebendazole or albendazole alone is not as
effective as a combined chemotherapy—drainage
approach. Treatment is typically administered as
1—6 monthly cycles separated by 10—14 day inter-
vals. Clinical and radiographic improvement (in
most studies defined as >25% reduction in cyst size,
membrane separation, or cyst calcification30) is
seen frequently, but complete cure (i.e. cyst dis-
appearance) generally occurs in less than half of
patients treated with anti-parasitic monother-
apy.10—14,17,26 Franchi and colleagues treated 448
patients with 3—6 month cycles of either albenda-
zole or mebendazole.9 Among 882 evaluable cysts,
74% showed degenerative changes on sonography or
CT imaging; the efficacy of albendazole (82%) was
superior to that of mebendazole (56%), confirming
previously reported experiences.31,32 However, 25%
of subjects showed evidence of cyst regeneration,
including an increase in size or fluid volume,
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membrane to the cyst wall. The rate of relapse
was similar for patients treated with either alben-
dazole or mebendazole but was more frequent for
cysts with a daughter cyst than for primary cysts,
and for cysts of the liver than those in the lung. More
than three quarters of relapses were noted within
two years after the end of the treatment, and,
importantly over 90% of these cysts regressed on
further antiparasitic therapy.
Future advances in chemotherapy may be
achieved by identifying drugs with higher echino-
coccal activity. For now, albendazole chemotherapy
as the primary treatment may be considered for
patients who are not acceptable candidates for
surgery, those with inoperable, recurrent, perito-
neal, or too many cysts, those with multiple cysts in
several organs, those who refuse surgery or percu-
taneous drainage, and perhaps, for asymptomatic
individuals.
Praziquantel
A third antiparasitic agent, praziquantel, has had
limited use in the treatment of hydatid cysts of the
liver. The drug, an isoquinolone derivative,
increases the permeability of the parasite’s cell
membrane to calcium, resulting in strong contrac-
tions and paralysis of the musculature leading to
detachment from host tissue.33 Praziquantel is an
effective scolicide in vitro and in animal models; in
humans, it has favorable pharmacokinetics when
given in a dose of 50 mg/kg either once weekly or
every two weeks.33
There are few clinical studies documenting the
efficacy of praziquantel in humans,34—38 however,
several of these have suggested that the use of
praziquantel in combination with mebendazole37
or albendazole34,38 is more effective and perhaps,
more rapid than with the benzimidazoles alone. For
41 patients with hepatic hydatid cysts treated with
either albendazole alone or albendazole plus prazi-
quantel, albendazole resulted in the complete dis-
appearance of the cyst in 36.4% of subjects with
treatment periods ranging from six months to two
years (four of these also required endoscopic treat-
ment for cure), while the combination led to the
complete disappearance of cysts in 47.4% after only
2—6 months of drug therapy.34 In a patient cohort
with intra-abdominal hydatidosis, a significantly
greater number of patients treated preoperatively
with albendazole plus praziquantel had nonviable
protoscolices at the time of surgery compared to
patients receiving albendazole alone, at doses of
both 10 mg/kg/day (p = 0.004) and 20 mg/kg/day
(p = 0.03).38 Albendazole sulfoxide levels in serumand in cyst fluid were higher in patients given
combination therapy than in those who received
only albendazole (10 mg/kg/day: p = 0.016;
20 mg/kg/day: p = 0.034).Surgical options
The goals of surgery in hydatid disease are to inac-
tivate the cestode parasites, evacuate the cyst
cavity, remove the germinal layer, and obliterate
the residual cavity. Surgical interventions consist of
conservative, radical, and laparoscopic approaches.
Conservative techniques involve simple tube drai-
nage, marsupialization (i.e. surgical exteriorization
of a cyst by resection of the anterior wall and suture
of the cut edges of the remaining cyst to the adja-
cent edges of the skin, thereby establishing a pouch
of what was formally an enclosed cyst), capitonnage
(i.e. surgical closure of a cyst cavity by applying
sutures so as to cause approximation of the opposi-
tion surfaces), deroofing, partial simple cystectomy,
or open or closed total cystectomy with or without
omentoplasty. Radical procedures include total
pericystectomy, partial hepatectomy, or lobectomy.
In the last decade, there has been a shift towards
radical surgical procedures because they appear to
result in fewer postoperative complications, fewer
relapses, and lower mortality than conservative
techniques.2,39 Laparoscopic drainage of hepatic
hydatid cysts is a ‘minimally invasive’ surgical tech-
nique that appears safe and effective.40—45 Which-
ever technique is used, a benzimidazole agent is
best used before any surgery in an attempt to
sterilize the cyst contents and reduce the risk of
anaphylaxis and dissemination.25
Meticulous packing of the operative field is neces-
sary irrespective of the surgical technique
employed, as is the use of solutions that kill the
infective scoleces and protoscolices of the parasite
residing within the hydatid cyst, or potentially leak-
ing from the cyst during surgical manipulation. Var-
ious scolicidal solutions used in surgical (and
percutaneous) approaches include: hypertonic sal-
ine, povidone iodine, hydrogen peroxide, iodine,
formalin, silver nitrate, and albendazole. These
scolicides can be used alone or in combination.
The type of scolicide used does not by itself sig-
nificantly influence the outcome of the surgical or
non-surgical intervention, but different solutions
have their own advantages and relative contraindi-
cations (see percutaneous drainage below).
Potential major complications associated with
the surgical treatment of hepatic hydatid cysts
include postoperative hemorrhage, bile exudation
from the residual cyst cavity, incisional fistula for-
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sional fistulae, pulmonary complications such as
pneumonia and pulmonary embolization,46 compli-
cations of anesthesia, and death.39,47—49 The
surgical intervention associated with the most com-
plications, longest mean hospital stay (about 20—28
days),47,49 and worst overall outcome is percuta-
neous tube drainage.
Percutaneous drainage
The availability of chemotherapeutic agents with
significant activity against Echinococcus granulosis
has made it possible to undertake transhepatic
percutaneous drainage of hydatid cysts. Several
techniques for percutaneous drainage for hydatid
cysts have been described,50—55 but here the litera-
ture is summarized for experience with the techni-
que known as the PAIR procedure (percutaneous
drainage consisting of puncture, aspiration, injec-
tion, and re-aspiration of scolicidal solutions). PAIR
treatment satisfies all the goals of surgery in hydatid
disease but substitutes germinal membrane scleros-
ing and separation using scolicides for surgical
removal.
Patients undergoing PAIR typically receive oral
albendazole or mebendazole for seven days before
and 28 days after drainage. Percutaneous drainage
of hepatic hydatid cysts without drug therapy has
been reported.6—8,56—58 However, concomitant pre-
and post-interventional chemotherapy with alben-
dazole or mebendazole offers the advantage of
reducing the risk of disease recurrence and intra-
peritoneal seeding of infection that may develop via
cyst rupture and spillage occurring spontaneously or
during needle puncture of cysts.
The procedure is typically performed in three
steps: puncture and needle aspiration of the cyst,
instillation and in-dwelling of a scolicidal solution
for about 20—30 minutes, and cyst re-aspiration and
final irrigation (complete cyst aspiration is generally
performed a single time, but in certain subjects
aspiration may be repeated until the aspirate is
clear). Facilities permitting, PAIR drainage is per-
formed under continuous ultrasonographic or CT
guidance with close monitoring for complications
such as anaphylaxis, bronchospasm, and laryngeal
edema.
Different scolicidal solutions can be used in PAIR,
although hypertonic saline is most commonly
employed. Hypertonic saline (in 5—30% concentra-
tions) exerts its scolicidal effect by creating a strong
osmotic gradient across the outer cuticular mem-
brane of the protoscolex, which causes its lysis. A
unique advantage of hypertonic saline is its high
density and attenuation on CT imaging which allowsassessment of the dilution of the solution within the
hydatid cyst cavity, evaluation of proper contact of
the solution with all internal parts of the cyst, and
detection of extra-hepatic biliary communications.
For multiseptate Type III cysts or large cysts over
6 cm in size, some authors advocate the use of
absolute alcohol because it is a more sclerosing
agent than hypertonic saline and may destroy
daughter cysts not killed by saline and may also
result in a more rapid involution of the cyst cav-
ity.16,27,59—65 Alcohol should not be used, however, if
pre-existing biliary communication is suspected or
documented because the agent may cause a che-
mical cholangitis.
With PAIR, cyst fluid or operative tissue speci-
mens are immediately subjected to cytologic, his-
topathologic, and parasitologic examinations after
aspiration or catheter drainage in order to confirm
the diagnosis and assess success of the drainage
procedure. Scolices, hooklets, (and/or fragments
of laminated membrane) are sought, and the viabi-
lity of protoscolices is assessed in cytologic/para-
sitologic (procedural or operative) specimens by
observing their motility and their staining pattern
using light microscopy and staining with neutral
eosin (demonstrating viable parasites) and methy-
lene blue (demonstrating dead organisms).66
With serial sonographic follow-up, the radio-
graphic response to PAIR plus albendazole therapy
evolves through a series of progressive changes in
echopattern. There is immediate detachment of the
germinal layer (endocyst) from the pericyst after
injection and aspiration of the scolicidal agent.
Subsequently, there is reduction in cyst size,
diminution of fluid contents, solidification of inter-
nal cyst structure (pseudotumor formation), and in
many patients eventual radiologic disappearance.
Microscopically, there is concomitant permanent
damage to the germinal membrane, and viable
protoscolices can be accurately distinguished from
non-viable protoscolices. Percutaneous drainage
can be performed utilizing a single needle puncture
for both univesicular and multivesicular cysts.59,67
Complications arising from PAIR therapy with
albendazole or mebendazole are generally well tol-
erated. Infections can be managed with systemic
antimicrobial therapy; leakage during drainage may
lead to fever, urticaria, transient hypotension, or
anaphylaxis but these can be anticipated and effec-
tively managed with antipyretics, iv fluids, antihis-
tamines, and subcutaneous epinephrine. Cyst-
biliary communications (biliary rupture and fistula
formation) developing after PAIR and caused by
cyst decompression, can usually be managed
endoscopically.65,68 Cholangiography or endoscopic
retrograde cholangiopancreatography (ERCP) is
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Table 1 Clinical outcomes in patients undergoing PAIR plus chemotherapy or surgical intervention for hepatic
echinococcosis.a,b
Clinical outcome No. of patients (%) p value
PAIR plus chemotherapy Surgical intervention
Cure 737/769c (95.8) 855/952 (89.8) <0.0001
Died 1/769 (0.1) 7/952 (0.7) <0.08
Insufficient response 15/769 (2.0) 30/952 (3.2) <0.12
Recurrence 12/769 (1.6) 60/952 (6.3) <0.0001
Re-PAIR or re-operation 9/769d (1.2) 18/952 (1.8) <0.23
a Reproduced with permission.
b References 2,3,16,27,46,48,50,51,56,59—65,70—84.
c Includes re-PAIR in five patients performed to accelerate healing.
d Includes one patient undergoing endoscopic retrograde cholangiopancreatography (ERCP) for biliary repair.recommended prior to any percutaneous drainage in
order to inject contrast dye and detect connections
with the biliary tree. Biliary connections may be
hidden prior to ERCP due to the distention of cysts
before aspiration, but become visible after injec-
tion of the contrast material.Table 2 Comparison of complications in patients with hep
vention.a,b
No
PAI
Major 6
Cyst infection 1
Liver or intra-abdominal abscess
Sepsis —
Biliary fistula 3
Anaphylaxis
Minor 10
Minor (not stated) —
Fever 4
Allergic reaction, urticaria, or pruritus 3
Pneumonia, pneumothorax, or pulmonary
complications (not stated)
Pleural effusions
Wound infection/dehiscence —
Prolonged tube drainage
Incisional hernia —
Hemorrhage
GI bleed —
Cholangitis —
Peritonitis —
Intraperitoneal leakage
Pancreatitis —
Deep venous thrombosis or pulmonary embolus —
Paralytic ileus —
Liver fibrosis or failure —
Transient hypotension
Stroke —
Transient elevated liver enzymes
Other drug-related
a Reproduced with permission.
b References 2,3,16,27,47,49,51,52,57,60,61—66,71—85.In a recent meta-analysis of 21 comparative or
non-comparative studies published from 1990 to
2001 involving a total of 769 albendazole- (15 stu-
dies; 663 subjects) or mebendazole-treated (eight
studies; 106 subjects) patients, the clinical out-
comes and rates of complications were comparedatic echinococcosis treated with PAIR or surgical inter-
. of patients (%)
R (n = 769) Surgery (n = 952) p value
1 (7.9) 239 (25.1) <0.0001
6 (2) 63 (6.6) <0.0001
3 (0.4) 34 (3.6) <0.0001
1 (0.1) NS
4 (4.4) 140 (14.7) <0.0001
8 (1.0) 1 (0.1) NS
1 (13.1) 314 (33.0) <0.0001
2 (0.2) NS
2 (5.5) 24 (2.5) <0.002
7 (4.8) 1 (0.1) <0.0001
1 (0.1) 32 (3.4) <0.0001
4 (0.5) 67 (7.0) <0.0001
63 (6.6) <0.0001
2 (0.3) 3 (0.3) NS
2 (0.2) NS
1 (0.1) 12 (1.3) <0.008
2 (0.2) NS
15 (1.6) NS
61 (6.4) <0.0001
1 (0.1) — NS
1 (0.1) NS
4 (0.4) NS
9 (0.9) NS
7 (0.7) NS
2 (0.3) — NS
1 (0.1) NS
9 (1.2) 4 (0.4) NS
8 (1.0) 4 (0.4) NS
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echinococcosis with those of era-matched historical
controls undergoing surgical intervention (952 sub-
jects from 14 previously published articles).69 Four
hundred and nineteen control patients received
albendazole or mebendazole in addition to surgery,
while 533 subjects underwent a surgical procedure
alone. Clinical and parasitologic cure occurred in
95.8% of patients undergoing PAIR and 89.8% of
surgical controls (p < 0.0001), and incomplete
response and disease recurrence in 2.0% and 3.2%
(p < 0.12) and 1.6% and 6.3% (p < 0.0001), respec-
tively (Table 1).
There was one procedure-related death in the
PAIR group due to anaphylaxis (0.1%) compared to
seven deaths (0.7%) among surgical controls
(p < 0.08). Causes of mortality in the controls
included pulmonary complications (3 patients),
liver failure (1), myocardial infarction (1), gener-
alized peritonitis (1), and spontaneous anaphylaxis
(1). Major (i.e. anaphylaxis, cyst infection, liver or
intra-abdominal abscess, sepsis, and biliary fis-
tula) and minor non-fatal complications occurred
in 7.9% and 13.1% (p < 0.0001) and 25.1% and 33%
(p < 0.0001) of PAIR and surgical control subjects,
respectively (Table 2). There was no instance of
dissemination (peritoneal seeding) using PAIR.
Easily managed fever and minor allergic reactions
were encountered more frequently in PAIR-treated
subjects compared to controls (5.5% and 2.5,
p < 0.002; and 4.8% and 0.1%, p < 0.0001, respec-
tively).Summary
In conclusion, compared to patients undergoing
surgical intervention for cystic hepatic echinococ-
cosis, PAIR plus albendazole or mebendazole is asso-
ciated with greater clinical and parasitologic
efficacy, less major andminor morbidity, lower rates
of mortality and disease recurrence, and a shorter
duration of hospitalization. As an initial treatment
option or for patients who fail drug therapy alone,
PAIR is a safe and effective procedure of choice for
patients with hepatic echinococcosis,4,5 and per-
haps other anatomic sites of infection such as lung,
peritoneum, kidney, and other viscera.86—89 There
are considerable potential economic and societal
savings inherent in the availability of a safe and
effective non-operative treatment modality for
hydatid cyst disease that reduces hospital stays by
84%. Surgery may be reserved for patients with
hydatid cysts refractory to PAIR because of second-
ary bacterial infection or with difficult-to-manage
cyst-biliary communication or obstruction.4,5Conflict of interest: No conflict of interest to
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